The prognostic importance of sentinel lymph node biopsy in thin melanoma

Annals of Surgical Oncology

Volumn 13, Issue 7, 2006, Pages 927-932

  Ranieri, Jaime M ^a   Wagner, Jeffrey D ^a,b   Wenck, Stacie ^a   Johnson, Cynthia S ^a   Coleman III, John J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Breslow level; Melanoma; Metastases; Prognosis; Sentinel lymph node; Tumor thickness

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LOG RANK TEST; MALE; MELANOMA; MITOSIS INDEX; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; THICKNESS; UNITED STATES; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 33745238097     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.04.023     Document Type: Article

References (24)

1. Lipsker DM, Hedelin G, Heid E, et al. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol 1999; 135:1451-6.
2. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48.
3. Woods JE, Soule EH, Creagan ET. Metastasis and death in patients with thin melanomas (< .76 mm). Ann Surg 1983; 198:63-4.
4. Mansson-Brahme E, Carstensen J, Erhardt K, et al. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994; 73:2324-32.
5. Slingluff CL, Vollmer RT, Reintgen DS, et al. Lethal "thin" malignant melanoma: identifying patients at risk. Ann Surg 1988; 208:150-61.
6. Naruns PL, Nizze JA, Cochran AJ, et al. Recurrence potential of thin primary melanomas. Cancer 1986; 57:545-8.
7. Corsetti RL, Allen HM, Wanebo HJ. Thin ≤1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol 2000; 7:456-60.
8. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002; 138:603-8.
9. Bedrosian I, Faries MB, Guerry D, et al. Incidence of sentinel node metastases in patients with thin primary melanoma (≤1 mm) with vertical growth phase. Ann Surg Oncol 2000; 7:262-7.
10. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 2003; 36:347-50.
11. Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000; 89:453-62.
12. Gershenwald JE, Thompson W, Mansfield PF, et al. Multiinstitutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-83.
13. Wagner JD, Ranieri J, Evdokimow DZ, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg 2003; 112:486-97.
14. Lowe JB, Hurst E, Moley JF, et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 2003; 139:617-21.
15. Muller MG, Leeuwen PA, vanDiest PJ, et al. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res 2001; 11:303-7.
16. Morton DL, Wen DR, Wong JH, et al. Technical details of intra-operative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-9.
17. Jacobs IA, Chang CK, DasGupta TK, et al. Role of sentinel lymph node biopsy in patients with thin (< 1 mm) primary melanoma. Ann Surg Oncol 2003; 10:558-61.
18. Nahabedian MY, Tufaro AP, Manson PN. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary? Ann Plast Surg 2003; 50:601-6.
19. Schmid-Wendtner MH, Baumert J, Schmidt M, et al. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients. Melanoma Res 2001; 11:619-26.
20. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic index is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97:1488-98.
21. Kesmodel SB, Karakousis GC, Botbyl JP, et al. Mitotic rate as a predictor for sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005; 12:449-58.
22. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-34.
23. Finley JW, Gibbs JF, Rodriguez LM, et al. Pathologic and clinical features influencing outcome of thin melanoma: correlation with newly proposed staging system. Am Surg 2000; 66:527-31.
24. Agnese DM, Abdessalam SF, Burak WE, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003; 134:542-7.